| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/20/2011 | US20110014216 Drug Transfer Based on Coenzyme A and Acyl Carrier Protein |
| 01/20/2011 | US20110014215 Granulysin and uses thereof |
| 01/20/2011 | US20110014214 Diagnostic and Therapeutic Utility of Tribbles-2 in Human Cancers |
| 01/20/2011 | US20110014213 Human anti-alpha 9 integrin antibody |
| 01/20/2011 | US20110014212 Certain Chemical Entities, Compositions and Methods |
| 01/20/2011 | US20110014211 Composition for neutralizing botulinus toxin type-a, and human anti-botulinus toxin type-a antibody |
| 01/20/2011 | US20110014210 Chlamydia vaccine |
| 01/20/2011 | US20110014209 Recombinant hcv e2 glycoprotein |
| 01/20/2011 | US20110014208 Method of Treating Osteoarthritis with an Antibody to NGF |
| 01/20/2011 | US20110014207 Combination treatment for non-hematologic malignancies |
| 01/20/2011 | US20110014206 Screening at least one individual for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor |
| 01/20/2011 | US20110014205 Methods and compositions for treating chronic pelvic pain syndrome |
| 01/20/2011 | US20110014204 Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2 |
| 01/20/2011 | US20110014203 Formulation |
| 01/20/2011 | US20110014202 Methods for Diagnosing and Treating Neuroendocrine Cancer |
| 01/20/2011 | US20110014201 Il-18 receptor antigen binding proteins |
| 01/20/2011 | US20110014200 Monoclonal antibody that suppresses thyrotropin receptor constitutive activity |
| 01/20/2011 | US20110014199 Novel anti-il 13 antibodies and uses thereof |
| 01/20/2011 | US20110014198 Anti-vegf antibodies |
| 01/20/2011 | US20110014197 Methods of treating pre-eclampsia or eclampsia |
| 01/20/2011 | US20110014196 Drug Transfer into Living Cells |
| 01/20/2011 | US20110014195 Use of therapeutic peptides for the treatment and prevention of cancer |
| 01/20/2011 | US20110014194 Methods for inhibiting angiogenesis using egfl8 antagonists |
| 01/20/2011 | US20110014193 Humanized anti-human alpha 9-integrin antibody |
| 01/20/2011 | US20110014192 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators |
| 01/20/2011 | US20110014191 Breast cancer expression profiling |
| 01/20/2011 | US20110014190 Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| 01/20/2011 | US20110014189 Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents |
| 01/20/2011 | US20110014188 TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease |
| 01/20/2011 | US20110014187 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes |
| 01/20/2011 | US20110014186 Arylsulfonamide-based matrix metalloprotease inhibitors |
| 01/20/2011 | US20110014185 Methods involving graf polypeptides |
| 01/20/2011 | US20110014184 Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions |
| 01/20/2011 | US20110014183 Mcam modulation and uses thereof |
| 01/20/2011 | US20110014182 Antigen binding proteins |
| 01/20/2011 | US20110014181 Microneedle Delivery Device and Methods of Using Same |
| 01/20/2011 | US20110014180 Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue |
| 01/20/2011 | US20110014153 Reinforced tissue graft |
| 01/20/2011 | US20110014124 Targeted atherosclerosis treatment |
| 01/20/2011 | US20110014122 Novel anti-igf-ir and/or anti-insulin/igf-i hybrid receptors antibodies and uses thereof |
| 01/20/2011 | US20110014119 Methods for Manipulating Phagocytosis Mediated by CD47 |
| 01/20/2011 | US20110014117 Anti-igf1r |
| 01/20/2011 | CA2803061A1 Vaccines and compositions against streptococcus pneumoniae |
| 01/20/2011 | CA2768485A1 Treatment of infections |
| 01/20/2011 | CA2768462A1 Improved anti-serum albumin binding single variable domains |
| 01/20/2011 | CA2768460A1 Antagonists, uses & methods for partially inhibiting tnfr1 |
| 01/20/2011 | CA2768343A1 Detoxified escherichia coli immunogens |
| 01/20/2011 | CA2768204A1 Gram-positive bacteria specific binding compounds |
| 01/20/2011 | CA2768186A1 Rsv f protein compositions and methods for making same |
| 01/20/2011 | CA2767673A1 Supralingual vaccines and applicators |
| 01/20/2011 | CA2765220A1 Methods for inhibiting yellow color and peroxide formation in a composition |
| 01/20/2011 | CA2763091A1 Production of polio virus at high titers for vaccine production |
| 01/19/2011 | EP2275818A2 Method for improved early recognition of the seroconversion of an antibody to hepatitis C |
| 01/19/2011 | EP2275575A2 Coding sequence haplotypes of the human BRCA2 gene |
| 01/19/2011 | EP2275574A2 Coding sequence haplotypes of the human BRCA2 gene |
| 01/19/2011 | EP2275572A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/19/2011 | EP2275571A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/19/2011 | EP2275570A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/19/2011 | EP2275557A1 Albumin fusion proteins |
| 01/19/2011 | EP2275554A2 Neisserial antigenic peptides |
| 01/19/2011 | EP2275553A2 Neisserial antigenic peptides |
| 01/19/2011 | EP2275552A2 Neisserial antigenic peptides |
| 01/19/2011 | EP2275551A2 Neisserial antigenic peptides |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275547A2 Polynucleotides and polypeptide sequences involved in the process of bonne remodeling |
| 01/19/2011 | EP2275544A2 Genes and polypeptides relating to human colon cancers |
| 01/19/2011 | EP2275541A2 Method for controlling the activity of immunologically functional molecule |
| 01/19/2011 | EP2275540A2 Method for controlling the activity of immunologically functional molecule |
| 01/19/2011 | EP2275537A1 Anti-human dlk-1 antibody having anti-tumor activity in vivo |
| 01/19/2011 | EP2275535A1 Animal cells and processes for the replication of influenza viruses |
| 01/19/2011 | EP2275450A1 Treatment with anti-ERBB2 antibodies |
| 01/19/2011 | EP2275447A1 Methods of inhibiting metastasis |
| 01/19/2011 | EP2275446A2 Antibodies to insulin-like growth factor I receptor |
| 01/19/2011 | EP2275445A2 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| 01/19/2011 | EP2275443A1 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| 01/19/2011 | EP2275435A2 Streptococcus agalactiae antigens I + II |
| 01/19/2011 | EP2275136A1 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
| 01/19/2011 | EP2275135A1 Therapeutic for hepatic cancer |
| 01/19/2011 | EP2275134A2 Use of ADCC-optimized antibodies for treating weak patients |
| 01/19/2011 | EP2275133A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
| 01/19/2011 | EP2275132A2 Multivalent PCV2 immunogenic compositions and methods of producing them |
| 01/19/2011 | EP2275131A2 HCV Vaccines |
| 01/19/2011 | EP2275130A2 PCV2 ORF2 immunogenic composition |
| 01/19/2011 | EP2275129A2 Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| 01/19/2011 | EP2275128A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275127A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275126A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275125A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275124A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275123A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275122A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275121A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275120A2 Protein-based streptococcus pneumoniae vaccines |
| 01/19/2011 | EP2275119A1 Stable isotonic lyophilized protein formulation |
| 01/19/2011 | EP2275115A2 Inhibition of stress-induced ligand-dependent EGFR activation |
| 01/19/2011 | EP2274416A2 Commensal bacteria as signal mediators within a mammalian host |
| 01/19/2011 | EP2274336A2 Mutants of streptokinase and their covalently modified forms |
| 01/19/2011 | EP2274333A2 Methods for treating psoriasis |
| 01/19/2011 | EP2274304A1 Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
| 01/19/2011 | EP2274012A1 Cytotoxic immunoglobulin |